Condition: Multiple Sclerosis, Relapsing-Remitting · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0114 | Loma Linda, California, United States | Not Yet Recruiting |
| University of California Davis Health | Sacramento, California, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Local Institution - 0093 | Chicago, Illinois, United States | Withdrawn |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Louisville, Norton Children's Research Institute | Louisville, Kentucky, United States | Recruiting |
| Local Institution - 0131 | New Brunswick, New Jersey, United States | Not Yet Recruiting |
| Local Institution - 0132 | Teaneck, New Jersey, United States | Withdrawn |
| Local Institution - 0091 | Cincinnati, Ohio, United States | Withdrawn |
| Local Institution - 0092 | Portland, Oregon, United States | Not Yet Recruiting |
| Local Institution - 0133 | El Paso, Texas, United States | Not Yet Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06408259